Please try another search
For the nine months ended 30 September 2011, TibetPharmaceuticals Inc revenues increased 7% to $25.6M. Netincome decreased 23% to $7.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Net income was offset bySelling, general and administrative expe increase of 24% to$2.6M (expense), Other Income (Expense) increase from $0Kto $3K (expense).
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Revenue | 8.58 | 8.75 | 8.24 | 202.54 |
Gross Profit | 2.95 | 3.87 | 3.47 | 26.36 |
Operating Income | 1.61 | 3.5 | 2.55 | 8.06 |
Net Income | 1.65 | 3.53 | 2.57 | 9.67 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Total Assets | 50.22 | 49.92 | 46.14 | 1319.21 |
Total Liabilities | 3.02 | 4.94 | 5.46 | 232.73 |
Total Equity | 47.2 | 44.98 | 40.67 | 1086.48 |
Period Ending: | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 3.27 | 7.05 | 2.79 | 89.44 |
Cash From Investing Activities | 0 | 0 | -3.91 | |
Cash From Financing Activities | 14.42 | 14.42 | 14.42 | -59.33 |
Net Change in Cash | 18.38 | 21.94 | 17.24 | 26.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review